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Abbreviations used: AcOH, acetic (ethanoic) acid; CDI, N,N’-carbonyldiimidazole; CoA, 
coenzyme A; DAST, diethylaminosulfur trifluoride; DBQ, 2,6-dichloro-1,4-benzoquinone; DCM, 
dichloromethane; ESI-TOF, electrospray ionisation-time-of-flight; HRMS (ES), High resolution 
mass spectrometry (electrospray); IPTG, isopropyl-β-D-thiogalactopyranoside; Pe, petroleum ether; 
PMSF, phenylmethylsulfonyl fluoride; THF, tetrahydrofuran; p.p.m., parts per million.  
Sources of materials: All reactions that require anhydrous conditions were performed under an 
argon atmosphere. Anhydrous and general grade solvents were purchased from the Sigma-Aldrich 
Chemical Co. and used without further purification unless otherwise noted. Oasis HLB cartridges 
were obtained from Waters Corporation. Biochemical grade reagents were purchased from the 
Sigma-Aldrich Chemical Co. or Fisher Scientific Ltd. Water for aqueous solutions was obtained 
from a Nanopure Diamond system and was of 18.2 MΩ.cm-1 quality. The Rosetta2 (DE3) 
expression strain was obtained from Novagen. Metal-chelate chromatography columns were from 
GE Healthcare. Construction of the expression plasmid for human AMACR has been previously 
described.1 Fenoprofenoyl-CoA was synthesised as previously described.2 
 
General experimental: Solvents were removed using Büchi rotary evaporators. Thin layer 
chromatography was performed on Merck silica aluminium plates 60 (F254) and UV light, 
potassium permanganate or phosphomolibdic acid were used for visualization. Column 
chromatography was performed using Fisher silica gel (particle size 35-70 micron). Purifications of 
acyl-CoA esters were performed by solid phase extraction using Oasis HLB 6cc (200 mg) 
extraction cartridges. Phosphate buffer was prepared from monobasic and dibasic potassium 
phosphates at the required proportion for 0.1 M pH 7.0 buffer. Optical rotations were recorded on 
an Optical Activity AA-10 Automatic polarimeter instrument. IR spectra were recorded on Perkin-
Elmer RXI FTIR spectrometer instrument. NMR spectra were recorded on Bruker Avance III 
400.04 MHz or 500.13 MHz spectrometers in D2O or CDCl3 and solvent was used as an internal 
standard. Shifts are given in ppm and J values reported to 0.1 Hz. Multiplicities of peaks are 
described as follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet. Stock concentrations of 
acyl-CoA esters for assays were determined using 1H NMR.2 Mass spectra were recorded by ESI-
TOF at the University of Bath Mass Spectrometry Service. High resolution mass spectra were 
recorded in ES mode. Optical rotations are reported in 10-1 deg cm2 g-1. Aqueous solutions for 
biological experiments were prepared in 18.2 MΩ.cm-1 Nanopure water and pH-adjusted with aq. 
HCl or NaOH as appropriate. Syntheses were carried out at ambient temperature, unless otherwise 
specified. 
 
Assignment of stereochemical configurations 
Configurations of chiral centres and double bonds are assigned based on the rules set forth by Cahn, 
Ingold and Prelog in 1966.3 Priorities of ligands in this paper are assigned in the following order: 
 
1) Atomic number (mass) of atoms; 
2) Atomic number (mass) of neighbouring atoms; 
3) Presence of double and triple bonds. 
In 3-fluoro-2-methylcarboxylic acids and their derivatives a change in the priority order at carbon 2 
occurs upon substitution of fluorine for the hydroxy group. In the aldol products the carboxylate 
amide or ester takes priority over the side-chain substituent, whilst the reverse is true in the 
fluorine-containing compounds (rule 2). A second change in priority order occurs upon going from 
the carboxylic acid to the acyl-CoA ester. This is because fluorine takes priority over oxygen and 
nitrogen, whilst sulfur takes priority over fluorine in the acyl-CoA ester (according to rule 2) 
(Scheme S1). Hence the relative orientation of ligands around carbon-2 does not change in this 
latter reaction but the stereochemical assignment changes due to changes in ligand priority. 
 
 
Scheme S1: Assignment of stereochemistry of compounds 
 
Syn- and anti- designation of 3-fluoro-2-methyldecanoyl-CoAs refer to the relative orientations of 
the methyl group and fluorine atom, whilst syn- and anti- elimination refers to the relative 
orientation of the α-proton and fluorine. 
 
Description of the AMACR reaction and its role in metabolic pathways 
AMACR catalyses an in vitro reaction in which either an R- or S-2-methylacyl-CoA ester is 
converted into a near 1:1 mixture of the C-2 epimers.1 The reaction differs from that of 2-
methylmalony-CoA epimerase,4,5 in which the product has the opposite configuration at the methyl 
centre to the substrate, i.e. the product is only one epimer. For convenience, the AMACR catalysed 
reaction is described as ‘racemisation’ to reflect the fact that both 2-methylacyl-CoA epimers are 
formed in the reaction. 
 
In vivo metabolism of 2-methyl fatty acids (as their corresponding acyl-CoA esters) occurs with a 
net R- to S- conversion of the chiral centre with the methyl group (C-2). This is because the S-2-
methylacyl-CoA ester is removed by β-oxidation, whilst the R-2-methylacyl-CoA ester is not a 
substrate for the branched-chain acyl-CoA oxidase.6-9 In the metabolism of IbuprofenTM and related 
2-APA drugs, the R-2-APA is specifically converted into the R-2-APA-CoA,10-15 which is acted on 
by AMACR. Hydrolysis of the ‘racemic’ (2R/S) product results in a mixture of R- and S-2-APA 
drug, but the R-2-APA undergoes further cycles of metabolism. Since the S-2-APA is not recycled 
in this way, a net R- to S- conversion occurs. This three enzyme metabolic pathway is generally 
referred to in the literature (reviewed in16) as ‘chiral inversion’. 
Synthesis of anti-3-fluoro-2-methyldecanoyl-CoA (2R) 
anti-3-Fluoro-2-methyldecanoyl-CoA 2R was synthesised by modification of the route to anti-3-
fluoro-2-methyldecanoic acid reported by Carnell et al.,17 using octanal in place of tetradecanal. 
Conversion of the acid to 2R was achieved using carbonyldiimidazole as previously reported.2 
 
 
 
Scheme S2:  Synthesis of anti-3-fluoro-2-methyldecanoyl-CoA 2R. Reagents and conditions: i. n-
BuLi, THF, propanoyl chloride, -78°C, 99%; ii. Bu2BOTf, Pr
i
2NEt, octanal, DCM, -78°C, 99%; iii. 
DAST, DCM, -78°C, 64%; iv. LiOH, H2O2, H2O/THF, 0°C, 61%; v. CDI, DCM, rt; vi. CoA-SH-
Li+3, 0.1 M NaHCO3 aq. /THF (1:1). 
(R)-4-Benzyl-3-propanoyloxazolidin-2-one (11) 
 
 
 
R-Evans’ auxiliary 10 (4.056 g, 23 mmol) in anhydrous THF (60 mL) was cooled to -78C, then n-
BuLi (1.6 M, 14.3 mL, 23 mmol) in THF was added dropwise and the resulting mixture was stirred 
at -78C for 30 min. A solution of propanoyl chloride (2.0 mL, 23 mmol) in anhydrous THF (20 
mL) was added dropwise and the reaction mixture was stirred at -78C for 30 min and then allowed 
to reach ambient temperature over a period of 1 h. The reaction mixture was quenched by slow 
addition of saturated aqueous NH4Cl (80 mL) and extracted with DCM (2 × 100 mL). The 
combined organic extracts were washed with saturated aq. NaHCO3 and brine. Drying (MgSO4), 
filtration, evaporation and column chromatography (Pe / EtOAc 4:1) to give 11 (5.31 g, 99 %) as a 
colourless solid. mp 44-46C, lit.18 43-46C. 1H NMR (400.04 MHz, CDCl3) δ 7.34-7.15 (5H, m), 
4.69-4.61 (1H, m), 4.21-4.12 (2H, m), 3.28 (1H, dd, J = 13.4, 3.3 Hz), 3.04-2.85 (2H, m), 2.76 (1H, 
dd, J = 13.4, 9.5 Hz), 1.18 (3H, t, J = 7.3 Hz).19 
(R)-4-Benzyl-3-[(2R,3S)-3-hydroxy-2-methyldecanoyl]oxazolidin-2-one (12) 
 
Dibutylboron triflate in DCM (1.00 M, 1.30 mL, 1.29 mmol) and diisopropylethylamine (0.25 mL, 
1.29 mmol) were added to a stirred solution of oxazolidinone 11 (300 mg, 2.14 mmol) in DCM (10 
mL) cooled to -78C and the solution was stirred for 30 min. Octanal (0.15 mL, 0.92 mmol) in 
DCM (3.0 mL) was added dropwise and the reaction mixture was stirred at -78C for 30 min, then 
allowed to reach ambient temperature. The reaction was quenched by slow addition of phosphate 
buffer (0.1 M, pH = 7, 10 mL). The organic layer was then washed with aq. hydrochloric acid (1 
M), saturated aq. NaHCO3 and brine. Drying (MgSO4), filtration, evaporation and column 
chromatography (Pe / EtOAc 10:1) gave 12 (330 mg, 99%) as a colourless oil: Rf=0.25 Pe:Et2O 1:1. 
[]21D = -59.3(CHCl3, c = 0.54); IR (liquid film, cm-1) 3514, 1783, 1698; 1H NMR (400.04 MHz, 
CDCl3) δ 7.36-7.17 (5H, m), 4.75-4.65 (1H, m), 4.26-4.16 (2H, m), 3.98-3.89 (1H, m), 3.76 (1H, dq 
J = 7.0, 2.7 Hz), 3.25 (1H, dd, J = 13.4, 3.3 Hz), 2.84-2.74 (2H, m), 1.35-1.22 (12H, m), 1.25 (3H, 
d, J = 7.0 Hz), 0.87 (3H, t, J = 7.0 Hz); 13C NMR (100.59 MHz) δ 177.42, 152.98, 135.03, 129.36, 
128.88, 127.33, 71,48, 67.85, 66.09, 55.04, 42.13, 37.72, 33.88, 31.74, 29.47, 25.95, 22.56, 14.00, 
10.40; HRMS (ES) ([M + Na]+) Calcd. for C21H31NNaO4: 384.2151, Found: 384.2198.  
 
(R)-4-Benzyl-3-[(2S,3R)-3-fluoro-2-methyldecanoyl]oxazolidin-2-one (13) 
 
 
 
Compound 12 (156 mg, 0.43 mmol) in anhydrous DCM (3.0 mL) was cooled to -78C, then DAST 
(57 µL, 0.43 mmol) in anhydrous DCM (2.0 mL) was added dropwise to the reaction mixture. The 
mixture was, stirred at -78C for 2 h, then allowed to reach ambient temperature. The reaction 
mixture was quenched by slow addition of water (5.0 mL). The organic layer was washed with 
saturated aq. NaHCO3 and brine. Drying (MgSO4), filtration, evaporation and column 
chromatography (Pe / EtOAc 10:1) gave 13 (101 mg, 64%) as a colourless oil: Rf=0.66 Pe:EtOAc 
5:1. []21D = -42.0(CHCl3, c=0.87). IR (liquid film, cm-1): 1781, 1670, 1498. 1H NMR (400.04 
MHz, CDCl3): δ 7.37-7.16 (5H, m), 4.87-4.64 (2H, m), 4.24-4.07 (3H, m), 3.26 (1H, dd, J = 13.4, 
3.3 Hz), 2.87-2.75 (1H, m), 1.55-1.22 (12H, m), 1.18 (3H, d, J = 7.0 Hz), 0.88 (3H, t, J = 6.8 Hz). 
13C NMR (125.76 MHz) δ 174.31 (d, J= 3.0 Hz), 153.04, 135.15, 129.38, 128.86, 127.30, 95.51, 
94.15, 66.11, 55.32, 41.95 (d, J= 21.2 Hz), 37.78, 31.97 (d, J= 21.0 Hz), 31.70, 29.18 (d, J= 27.0 
Hz), 24.48 (d, J= 2.8 Hz), 22.55, 14.01, 13.54 (d, J= 8.3 Hz). 19F NMR (470.52 MHz) δ -179.69. 
HRMS (ES) ([M + Na]+) Calcd. for C21H30FNNaO3: 386.2107, Found: 386.2096. 
 
(2S,3R)-3-Fluoro-2-methyldecanoic acid (5) 
 
 
 
Oxazolidinone 13 (100 mg, 0.28 mmol) in THF (3.0 mL) was cooled to 0C, then 30% (v/v) aq. 
H2O2 (0.14 mL, 1.7 mmol) and LiOH (13 mg, 0.55 mmol) were added and the reaction mixture was 
stirred for 12 h. The reaction mixture was quenched by addition of saturated aq. Na2SO3 (3.0 mL) 
and was extracted with DCM. The organic phase was washed with water and brine. Drying 
(MgSO4), filtration, evaporation and column chromatography (Pe / EtOAc 5:1) gave 5 (34 mg, 
61%) as a colourless solid. mp 63-65C; []21D = +0.74 (CHCl3, c = 0.35); 1H NMR (400.04 MHz, 
CDCl3) δ 10.56 (1H, br s), 4.78-4.57 (1H, m), 2.85-2.71 (1H, m), 1.45-1.18 (12H, m), 1.19 (3H, d, J 
= 7.2 Hz), 0.87 (3H, t, J = 7.0 Hz). 13C NMR (125.76 MHz) δ 179.93 (d, J= 5.6 Hz), 94.28 (d, J= 
172.1 Hz), 44.36 (d, J= 22.1 Hz), 31.74 (d, J= 21.2 Hz), 31.74, 29.30, 29.12, 24.82 (d, J= 2.8 Hz), 
22.61, 14.06, 12.56 (d, J= 6.6 Hz); 19F NMR (470.52 MHz) δ -181.96. HRMS (ES) ([M - H+]-) 
Calcd. for C11H20FO2: 203.1447, Found: 203.1447. 
 
(2R,3R)-3-Fluoro-2-methyldecanoyl-CoA (2R) 
 
 
 
 
Acid 5 (10 mg, 0.05 mmol) in anhydrous DCM (1.0 mL) was treated with N,N’-
carbonyldiimidazole (14 mg, 0.09 mmol) in one portion and the mixture was stirred for 1 h. The 
mixture was washed with water (5 × 2 mL) and brine. Drying (MgSO4), filtration and evaporation 
gave the crude imidazolide. This material was dissolved in THF (1.0 mL) and CoA-Li3 (17 mg, 0.02 
mmol) was added, followed by aq. NaHCO3 (0.1 M, 1.0 mL) and the mixture was stirred for 18 h. 
The solution was acidified to pH ~3 with aq. HCl (1 M) and the solvents were partly removed under 
reduced pressure. Water (2.0 mL) was added and the mixture was washed with EtOAc (5 × 3 mL). 
Solid-phase extraction of the aqueous layer gave 2R (6.0 mg) as white powder: 1H NMR (500.13 
MHz, D2O) δ 8.47 (1H, s), 8.18 (1H, s), 6.07 (1H, d, J = 7.1 Hz), 4.18-4.11 (1H, m), 3.92 (1H, s), 
3.71-3.68 (1H, s), 3.57 (1H, d, J = 4.6 Hz), 3.55 (1H, d, J = 4.6 Hz), 3.49-3.43 (2H, m), 3.37-3.33 
(1H, m), 3.28-3.23 (1H, m), 3.17 (2H, t, J = 6.5 Hz), 2.99-2.91 (2H, m), 2.61 (2H, t, J = 6.5 Hz), 
2.32 (2H, t, J = 6.5 Hz), 1.25-1.09 (10H, m), 1.04 (3H, d, J = 7.1 Hz), 0.79 (3H, s), 0.75 (3H, t, J = 
6.9 Hz), 0.67 (3H, s); 19F NMR (470.52 MHz) δ -181.08; HRMS (ES) ([M - H+]-) Calcd. for 
C32H54FN7SO17P3: 952.2494, Found: 952.2528. 
 
Synthesis of syn-3-fluoro-2-methyldecanoyl-CoA (2S) 
syn-3-Fluoro-2-methyldecanoyl-CoA 2S was synthesised (Scheme S3a) by condensation of 2-
octenal with propanoyl-Evans’ auxiliary 11 to give the unsaturated aldol product 14. Hydrogenation 
over Pd/C gave the desired saturated compound 15. The Evan’s auxiliary was exchanged for the 
methyl ester 16, which was converted to the fluorinated compound 17 and deprotected under acid 
conditions to give 6. Conversion to the acyl-CoA ester 2S was accomplished using the general 
literature procedure.2 Direct treatment of 15 with DAST resulted in an unexpected rearrangement 
(Scheme S3b) via intermediate 18 to give product 19. This is believed to result from steric 
hindrance of the α-methyl group to the nucleophilic attack of the fluoride on the derivatised 
hydroxy group. Instead fluoride performs a nucleophilic attack on the oxazolidin-2-one ring.  
 
Scheme S3: a) Synthesis of syn-3-fluoro-2-methyldecanoyl-CoA 2S. Reagents and conditions: i. 
Bu2BOTf, Pr
i
2Net, 2-octenal, Et2O, -78°C, 30%; ii. H2, Pd/C, MeOH, 87%; iii. NaOMe, MeOH, 
0°C, 56%; iv. DAST, DCM, -78°C, 41%; v. aq. HCl, AcOH, 100°C, 50%; vi. CDI, DCM, rt; vii. 
CoA-SH-Li+3, 0.1 M NaHCO3 aq. / THF (1:1); b) Unexpected rearrangement of 15 upon treatment 
with DAST. Reagents and conditions: iv. DAST, DCM, -78°C, 99%. 
(R)-4-Benzyl-3-[(2S,3S,E)-3-hydroxy-2-methyldec-4-enoyl]oxazolidin-2-one (14) 
 
A solution of dibutylboron triflate in DCM (1.0 M, 1.7 mL, 1.71 mmol) and diisopropylethylamine 
(0.17 mL, 0.99 mmol) were added to 11 (200 mg, 0.86 mmol) in Et2O (5.0 mL) at 0 ˚C and the 
solution was stirred for 30 min. The reaction mixture was cooled to -78C and 2-octenal (0.16 mL, 
1.1 mmol) in Et2O (1.0 mL) was added dropwise. The reaction mixture was stirred at -78C for 30 
min and then allowed to reach ambient temperature. The reaction was quenched by slow addition of 
aq. phosphate buffer (0.1 M, pH = 7, 7 mL) and the organic layer was washed with aq. HCl (1.0 M), 
saturated aq. NaHCO3 and brine. Drying (MgSO4), filtration, evaporation and column 
chromatography (Pe / EtOAc 10:1) gave 14 (92 mg, 30%) as colourless oil: Rf=0.37 Pe:EtOAc 5:1. 
[]21D = +49.8 (CHCl3, c = 0.58). IR (liquid film, cm-1): 3498, 1780, 1698; 1H NMR (400.04 MHz, 
CDCl3) δ 7.37-7.20 (5H, m), 5.83-5.69 (1H, m), 5.56-5.46 (1H, m), 4.74-4.64 (1H, m), 4.27-4.12 
(3H, m), 3.98-3.89 (1H, m), 3.30 (1H, dd, J = 13.5, 3.4 Hz), 2.83-2.72 (1H, m), 2.51 (1H, d, J = 7.0 
Hz), 2.10-2.01 (2H, m), 1.44-1.23 (6H, m), 1.16 (3H, d, J = 7.1 Hz), 0.87 (3H, t, J = 7.0 Hz); 13C 
NMR (125.76 MHz) δ 176.02, 153.35, 135.17, 133.74, 129.34, 128.91, 128.73, 127.32, 73.24, 
66.07, 55.35, 42.75, 37.98. 32.18, 31.33, 28.73, 22.42, 13.93, 11.22. HRMS (ES) ([M + Na+]+) 
Calcd. for C21H31NNaO4: 382.1994, Found: 382.2054.  
 
(R)-4-Benzyl-3-[(2S,3S)-3-hydroxy-2-methyldecanoyl]oxazolidin-2-one (15) 
 
 
 
Aldol 14 (150 mg, 0.42 mmol) in EtOAc (10 mL) was stirred vigorously under hydrogen in the 
presence of 10 % Pd/C (10 mass%, 15 mg) for 1 d. The mixture was filtered (Celite) and the solvent 
was evaporated. Column chromatography (Pe / EtOAc 5:1) gave 15 (132 mg, 87 %) as a colourless 
oil: Rf=0.37 Pe:EtOAc 5:1. []21D = -40.0(CHCl3, c = 0.5). IR (liquid film, cm-1) 3524, 1780, 
1698; 1H NMR (400.04 MHz, CDCl3) δ 7.38-7.19 (5H, m), 4.74-4.63 (1H, m), 4.25-4.14 (2H, m), 
3.94-3.84 (1H, m), 3.78-3.66 (1H, m), 3.33 (1H, dd, J = 13.4, 3.3 Hz), 2.81-2.72 (1H, m), 2.51 (1H, 
d, J = 8.6 Hz), 1.65-1.23 (12H, m), 1.21 (3H, d, J = 6.8 Hz), 0.88 (3H, t, J = 7.0 Hz). 13C NMR 
(100.59 MHz) δ 176.84, 153.49, 135.21, 129.38, 128.89, 127.28, 74.61, 65.98, 55.48, 43.22, 37.82, 
34.95, 31.75, 29.48, 29.18, 25.40, 22.57, 14.55, 14.01; HRMS (ES) ([M + Na+]+) Calcd. for 
C21H31NNaO4: 384.2151, Found: 384.2198. 
 
(2S,3S)-Methyl 3-hydroxy-2-methyldecanoate (16) 
 
 
 
Sodium (48 mg, 2.1 mmol) was stirred with anhydrous MeOH (15 mL) until dissolved then cooled 
to 0 ̊C. Aldol 15 (470 mg, 1.30 mmol) in anhydrous MeOH (5.0 mL) was added and the mixture 
was stirred at 0 ̊C for 15 min. The reaction mixture was quenched by slow addition of aq. phosphate 
buffer (0.1 M, pH = 7, 20 mL) and extracted with DCM (4 × 20 mL). The combined organic layers 
were washed with brine and dried (MgSO4). Filtration, evaporation and column chromatography 
(Pe / EtOAc 5:1) gave 16 (158 mg, 56%) as a colourless oil. Rf=0.67 Pe:EtOAc 5:1.  []21D = +5.9 
(CHCl3, c = 1.0); 
1H NMR (400.04 MHz, CDCl3) δ 3.70 (3H, s), 3.65 (1H, br s), 2.58-2.44 (2H, m), 
1.60-1.22 (12H, m), 1.20 (3H, d, J = 7.2 Hz), 0.87 (3H, t, J = 7.0 Hz). 13C NMR (100.59 MHz) δ 
176.39, 73.32, 51.60, 45.11, 34.71, 31.73, 29.45, 29.16, 25.44, 22.56, 14.26, 13.99. HRMS (ES) 
([M + Na+]+) Calcd. for C12H24NaO3: 239.1623, Found: 239.1634. 
 
 
(2R,3R)-Methyl 3-fluoro-2-methyldecanoate (17) 
 
 
 
Compound 17 was prepared from 16 (54 mg, 0.25 mmol), following the same procedure as for 13. 
The product was purified by column chromatography (Pe / EtOAc 20:1) to give 17 (42 mg, 78%) as 
a colourless oil: Rf=0.41 Pe:EtOAc 20:1. []21D = +9.1 (CHCl3, c = 0.55).1H NMR (400.04 MHz, 
CDCl3): δ 4.80-4.59 (1H, m), 3.70 (3H, s), 2.71-2.55 (1H, m), 1.59-1.20 (12H, m), 1.23 (3H, d, J = 
7.1 Hz), 0.87 (3H, t, J = 7.0 Hz). 13C NMR (125.76 MHz) δ 174.02 (d, J= 7.8 Hz), 94.06 (d, J= 
173.7 Hz), 51.87, 44.19 (d, J= 22.8 Hz), 32.91 (d, J= 21.0 Hz), 31.73, 29.27, 29.11, 25.23 (d, J= 
3.8 Hz), 22.61, 14.06, 11.59 (d, J= 5.4 Hz). 19F NMR (470.52 MHz) δ -189.85. 
 
(2R,3R)-3-Fluoro-2-methyldecanoic acid (6) 
 
 
Methyl ester 17 (19 mg, 0.09 mmol) in acetic acid (1.0 mL) and aq. HCl (12 M, 1.0 mL) was heated 
at 100C for 4 h. The mixture was cooled to ambient temperature and the solvents were evaporated 
under reduced pressure. The residue, in DCM, was washed with water (twice) and brine. Drying 
(MgSO4), filtration, evaporation and column chromatography (Pe / EtOAc 2:1) gave 6 (9 mg, 50%) 
as a colourless oil; Rf=0.61 Pe:EtOAc 2:1; []21D = +7.5 (CHCl3, c = 0.4); 1H NMR (400.04 MHz, 
CDCl3) δ 10.38 (1H, br s), 4.86-4.64 (1H, m), 2.73-2.59 (1H, m), 1.53-1.19 (15H, m), 0.88 (3H, t, J 
= 6.9 Hz); 19F NMR (470.52 MHz) δ -190.19. HRMS (ES) ([M - H+]-) Calcd. for C11H20FO2: 
203.1447, Found: 203.1452. 
 
(2S,3R)-3-Fluoro-2-methyldecanoyl-CoA (2S) 
 
  
 
Compound 2S was prepared from 6 (7 mg), following the same procedure as for compound 2R to 
give 2 mg of 2S. 1H NMR (500.13 MHz, D2O) δ 8.71 (1H, s), 8.48 (1H, s), 6.30-6.20 (1H, m), 4.67-
4.58 (1H, m), 4.36-4.24 (2H, m), 4.11-4.02 (1H, m), 3.96-3.85 (1H, m), 3.70-3.57 (1H, m), 3.55-
3.34 (2H, m), 3.15-2.99 (2H, m), 2.59-2.40 (2H, m), 2.31-2.17 (1H, m), 1.84 (2H, s), 1.50-1.16 
(10H, m), 0.97 (3H, d, J = 6.5 Hz), 0.86 (3H, s), 0.84 (3H, s); 19F NMR (470.52) δ -187.20. 
 
 (5R,6S)-3-[(S)-1-Fluoro-3-phenylpropan-2-yl]-6-heptyl-5-methyl-1,3-oxazinane-2,4-dione (19) 
 
 
 
Compound 19 was prepared following the synthesis of 13 from 15 (115 mg, 0.32 mmol). Product 
was purified by column chromatography (Pe:EtOAc 20:1) to give 116 mg (99 %) of 19 as a 
colourless oil. Rf=0.72 Pe:EtOAc 5:1. [α]21D = +66.7 (CHCl3, c = 0.87). IR (neat, cm-1): 1754.82, 
1704.78. 1H NMR (500.13 MHz, CDCl3): δ 7.29-7.14 (5H, m), 5.49-5.31 (1H, m), 4.92 (1H, dt, J = 
48.4, 9.1 Hz), 4.59 (1H, ddd, J = 45.4, 9.4, 5.1 Hz), 4.24-4.12 (1H, m), 3.21 (1H, dd, J = 13.6, 11.1 
Hz), 2.99 (1H, dd, J = 13.6, 6.2 Hz), 2.61 (1H, dq, J = 7.2, 3.9 Hz), 1.40-1.14 (12H, m), 0.87 (3H, t, 
J = 7.1 Hz), 0.82 (3H, d, J = 7.2 Hz). 13C NMR (125.76 MHz) δ 172.53, 150.57, 136.27, 129.19, 
128.44, 126.80, 81.79 (d, J = 171.1 Hz), 77.03, 53.66 (d, J = 17.7 Hz), 39.15, 33.44 (d, J = 5.9 Hz), 
31.61, 29.13, 28.93 (d, J = 4.7 Hz), 24.96, 23.77, 22.51, 13.98, 9.10. 19F NMR (470.59 MHz) δ -
221.77. HRMS (ES) ([M + Na]+) Calcd. for C21H30FNNaO3: 386.2102, Found: 386.2102. 
 
Synthesis of S- and R- E-2-methyldec-3-enoyl-CoA esters (3S) and (3R) 
Synthesis of S- and R-E-2-methyldec-3-enoyl-CoA esters 3S and 3R was accomplished by reaction 
of the Grignard reagent from crotyl chloride 8 with CO2 to form the key unsaturated intermediate 
20. Derivatisation with R-Evan’s auxiliary 10 allowed separation of the diastereoisomers 21S and 
21R, which reacted with oct-1-ene in a metathesis reaction to give 22S and 22R. Deprotection 
afforded the required acids 7S and 7R, which were esterified with CoA-SH as previously 
described.2 
 
Scheme S4: Synthesis of E-2-methyldec-2-enoyl-CoA esters 3S and 3R. Reagents and conditions: 
i. Mg, I2, THF, reflux; ii. CO2, -78°C, H3O
+, 55%; iii. n-BuLi, (COCl)2, R-Evan’s auxiliary 10, 
THF, -78°C, 13% (21S) and 19% (21R); iv. 1-Octene, Hoveyda-Grubbs 2nd Generation cat., DBQ, 
DCM, reflux, 80% (22S) and 65% (22R); v. LiOH, H2O2, H2O/THF (1:1), room temperature, 98% 
(7S) and 99% (7R); vi. CDI, DCM, rt; vii. CoA-SH-Li+3, 0.1M NaHCO3 aq. / THF (1:1). 
 
()-2-Methylbut-3-enoic acid (20) 
 
 
 
Under strictly dry conditions, Mg turnings (275 mg, 11.3 mmol) were stirred with iodine (2 mg) in 
anhydrous THF (10 mL) for 30 min. Crotyl chloride 8 (2 drops)  (E-1-chlorobut-2-ene) was added 
to initiate reflux and the remaining 8 (1.00 mL, 10.3 mmol) was added dropwise, maintaining gentle 
reflux. The reaction mixture was stirred at ambient temperature for 30 min, then cooled to -78C. 
CO2 from dry ice was passed through concentrated sulfuric acid and bubbled through the mixture 
for 30 min. The reaction mixture was then allowed to reach ambient temperature under a flow of 
CO2. The reaction mixture was basified to pH 11 with aq. NaOH (4 M) and was washed with Et2O 
(3 × 30 mL). The aqueous layer was separated and acidified to pH 2 with aq. HCl (1 M) and 
extracted with Et2O (2 × 30 mL). The combined organic layers were washed with brine and dried 
(MgSO4). The solution was filtered and the solvent was evaporated to give 20 (560 mg, 55%) as a 
colourless liquid: 1H NMR (400.04 MHz, CDCl3) δ 11.01 (br s, 1H), 5.93 (1H, ddd, J= 17.4, 10.3, 
7.4 Hz), 5.21-5.12 (1H, m), 3.23-3.12 (m, 1H), 1.30 (d, 3H, J = 7.1 Hz). 
 
(R)-4-Benzyl-3-[(R)-2-methylbut-3-enoyl]oxazolidin-2-one (21R) and (R)-4-benzyl-3-[(S)-2-
methylbut-3-enoyl]oxazolidin-2-one (21S) 
 
 
 
Oxalyl chloride (1.60 mL, 18.7 mmol) was added dropwise to 20 (0.940 g, 9.40 mmol) in CHCl3 
(15 mL) at 0C. The reaction mixture was stirred at ambient temperature for 3 h. Evaporation of the 
solvent and excess reagent gave the corresponding acid chloride. n-BuLi (8.4 mL, 1.6 M, 13 mmol) 
in THF was added dropwise to 10 (1.165 g, 9.40 mmol) in anhydrous THF (20 mL) at -78C and 
the mixture was stirred for 30 min. The acid chloride in anhydrous THF (5.0 mL) was added 
dropwise. The reaction mixture was stirred at -78C for 1 h and was then allowed to reach ambient 
temperature. The reaction mixture was quenched by slow addition of saturated aq. NH4Cl (25 mL) 
and was extracted with DCM (2 × 50 mL). The combined organic layers were washed with 
saturated aq. NaHCO3 and brine. Drying (MgSO4), filtration, evaporation and column 
chromatography (Pe / EtOAc 10:1) gave 21R (467 mg, 19%) as a colourless oil. []21D = -84.4 
(CHCl3, c = 1.2), lit.
20 -87.3. 1H NMR (400.04 MHz, CDCl3) δ 7.37-7.16 (5H, m), 5.98 (1H, ddd, 
J= 7.7, 10.3, 17.4 Hz), 5.19 (1H, ddd, J= 1.2, 1.2, 17.4 Hz), 5.13 (1H, ddd, J= 1.0, 1.2, 10.3 Hz), 
4.70-4.61 (1H, m), 4.51-4.41 (1H, m), 4.22-4.14 (2H, m), 3.28 (1H, dd, J = 3.3, 13.4 Hz), 2.78 (1H, 
dd, J = 9.6, 13.4 Hz), 1.34 (d, 3H, J = 6.9 Hz). 
 
Further elution gave 21S (311 mg, 13%) as a white solid:  mp 69-71C, lit.20 72-74C; []21D = -
32.8 (CHCl3, c = 0.43), lit.20 -28.9. 1H NMR (400.04 MHz, CDCl3) δ 7.36-7.17 (5H, m), 6.02 
(1H, ddd, J = 7.6, 10.3, 17.5 Hz), 5.26 (1H, ddd, J =  1.1, 1.2, 17.5 Hz), 5.19 (1H, ddd, J = 1.0, 1.1, 
10.3 Hz), 4.73-4.65 (1H, m), 4.53-4.43 (1H, m), 4.24-4.12 (2H, m), 3.25 (1H, dd, J = 3.3, 13.4 Hz), 
2.74 (1H, dd, J = 9.5, 13.4 Hz), 1.31 (3H, d, J = 6.9 Hz).  
 
(R)-4-Benzyl-3-[(S,E)-2-methyldec-3-enoyl]oxazolidin-2-one (22S) 
 
Grubbs’ catalyst (Hoveyda-Grubbs Catalyst, 2nd Generation) (37 mg, 0.06 mmol) and DBQ (21 mg, 
0.12 mmol) were stirred in anhydrous DCM (3.0 mL) for 5 min, then 21S (305 mg, 1.18 mmol) and 
octene (0.37 mL, 2.35 mmol) in anhydrous DCM (2.0 mL) were added. The reaction mixture was 
stirred at reflux for 40 h. Evaporation and column chromatography (Pe / EtOAc 20:1) gave 22S 
(324 mg, 80%) as a colourless oil: Rf=0.57 Pe:EtOAc 5:1.  [α]21D  = -23.5 (CHCl3, c = 1.53); IR 
(liquid film, cm-1) 1782, 1700; 1H NMR (400.04 MHz, CDCl3) δ 7.34-7.16 (5H, m), 5.74-5.53 (2H, 
m), 4.73-4.64 (1H, m), 4.49-4.38 (1H, m), 4.22-4.10 (2H, m), 3.22 (1H, dd, J = 13.4, 3.4 Hz), 2.78-
2.69 (1H, m), 2.08-2.00 (2H, m), 1.41-1.23 (11H, m), 0.87 (3H, t, J = 7.0 Hz); 13C NMR (100.59 
MHz) δ 175.21, 152.91, 135.21, 133.32, 129.42, 128.83, 128.37, 127.24, 65.81, 55.09, 40.45, 37.68, 
32.49, 31.62, 29.10, 28.72, 22.55, 17.23, 13.99. HRMS (ES) ([M + Na+]+) Calcd. for C21H29NNaO3: 
366.2040, Found: 366.2077. 
 
(R)-4-Benzyl-3-[(R,E)-2-methyldec-3-enoyl]oxazolidin-2-one (22R) 
 
 
 
Compound 22R was prepared from 21R (460 mg, 1.77 mmol), following the same procedure as for 
compound 22S. The product was purified by column chromatography (Pe / EtOAc 20:1) to give 
22R (396 mg, 65 %) as a colourless oil:  Rf=0.70 Pe:EtOAc 5:1. []21D = -85.3 (CHCl3, c = 1.98); 
IR (liquid film, cm-1) 2957, 2927, 2872, 2856, 1783, 1699, 1455, 1382, 1355, 1210, 1104, 973, 703; 
1H NMR (400.04 MHz, CDCl3) δ 7.35-7.17 (5H, m), 5.65-5.50 (2H, m), 4.68-4.58 (1H, m), 4.45-
4.36 (1H, m), 4.17-4.12 (2H, m), 3.27 (1H, dd, J = 13.3, 3.2 Hz), 2.82-2.73 (1H, m), 2.04-1.95 (2H, 
m), 1.39-1.20 (11H, m), 0.87 (3H, t, J = 7.0 Hz). 13C NMR (100.59 MHz) δ 175.39, 152.88, 135.32, 
133.10, 129.37, 128.86, 128.41, 127.26, 65.94, 55.48, 40.72, 37.92, 32.41, 31.65, 29.02, 28.68, 
22.52, 18.74, 15.06. HRMS (ES) ([M + Na+]+) Calcd. for C21H29NNaO3: 366.2040, Found: 
366.2063. 
 
(2S,E)-2-Methyldec-3-enoic acid (7S) 
 
 
Compound 7S was prepared from oxazolidinone 22S (200 mg, 0.58 mmol), following the same 
procedure as for compound 5. The product was purified by column chromatography (Pe / EtOAc 
5:1) to give 7S (106 mg, 99 %) as a colourless oil: Rf=0.45 Pe:EtOAc 5:1. []21D = +32.0 (CHCl3, 
c = 0.77) (lit.21 []20D = +42.2 (DCM, c = 1.0); 1H NMR (400.04 MHz, CDCl3) δ 11.08 (1H, br s), 
5.64-5.44 (2H, m), 3.11 (1H, dq, J= 7.1, 7.0 Hz), 2.06-1.94 (2H, m), 1.41-1.20 (11H, m), 0.88 (3H, 
t, J = 6.9 Hz); 13C NMR (100.59 MHz) δ 181.35, 132.92, 127.93, 42.61, 32.32, 31.59, 29.02, 28.70, 
22.51, 17.18, 13.96. 
 
(2R,E)-2-Methyldec-3-enoic acid (7R) 
 
 
Compound 7R was prepared from oxazolidinone 22R (200 mg, 0.58 mmol), following the same 
procedure as for compound 5. The product was purified by column chromatography (Pe / EtOAc 
5:1) to give 7R (105 mg, 98 %) as a colourless oil: Rf=0.45 Pe:EtOAc 5:1. []21D = -45.9 (CHCl3, c 
= 0.43) 1H NMR (500.13 MHz, CDCl3) δ 11.02 (1H, br s), 5.57-5.39 (2H, m), 3.05 (1H, dq, J= 7.1, 
7.0 Hz), 1.98-1.90 (2H, m), 1.34-1.14 (11H, m), 0.81 (3H, t, J = 6.9 Hz). 13C NMR (125.76 MHz) δ 
181.55, 133.04, 127.95, 42.72, 32.43, 31.69, 29.10, 28.80, 22.62, 17.28, 14.10. HRMS (ES) ([M - 
H+]-) Calcd. for C11H19O2: 183.1385, Found: 183.1551. 
 
(2S,E)-2-Methyldec-3-enoyl-CoA (3S) 
 
Compound 3S was prepared from 7S (15 mg), following the same procedure as for compound 2R to 
give 4 mg of 3S. 1H NMR (500.13 MHz, D2O): δ 8.47 (1H, s), 8.18 (1H, s), 6.08 (1H, d, J = 7.1 
Hz), 4.70-4.67 (1H, m), 4.20-4.08 (2H, m), 3.93 (1H, s), 3.77-3.70 (1H, m), 3.62 (1H, s), 3.48-3.42 
(1H, m), 3.39-3.31 (2H, m), 3.27-3.20 (2H, m), 2.96-2.82 (1H, m), 2.32 (2H, t, J = 6.8 Hz), 1.88 
(1H, q, J = 6.9 Hz), 1.26-1.04 (11H, m), 0.80 (3H, s), 0.73 (3H, t, J = 6.5 Hz), 0.68 (3H, s).  
 
(2R,E)-2-Methyldec-3-enoyl-CoA (3R) 
 
Compound 3R was prepared from 7R (15 mg), following the same procedure as for compound 2R 
to give 6 mg of 3R. 1H NMR (500.13 MHz, D2O): δ 8.47 (1H, s), 8.18 (1H, s), 6.07 (1H, d, J = 7.1 
Hz), 4.71-4.67 (1H, m), 4.20-4.08 (2H, m), 3.92 (1H, s), 3.78-3.71 (1H, m), 3.62 (1H, s), 3.48-3.42 
(1H, m), 3.38-3.31 (2H, m), 3.27-3.20 (2H, m), 2.96-2.82 (1H, m), 2.32 (2H, t, J = 6.8 Hz), 1.88 
(1H, q, J = 6.9 Hz), 1.31-1.03 (11H, m), 0.80 (3H, s), 0.74 (3H, t, J = 6.5 Hz), 0.68 (3H, s). 
 
Synthesis of E-2-methyldec-2-enoyl-CoA (4) 
Ylide 23 was prepared using the method of Baktharaman et al.22 and the desired unsaturated ester 
24 prepared by Wittig reaction between ylide 23 and octanal. Ester 24 was hydrolysed to the acid 9 
under basic conditions, which was converted to 4 by the literature procedure.2  
 
 
Scheme S5: Synthesis of E-2-methyldec-2-enoyl-CoA 4. Reagents and conditions: i. Octanal, 
DCM, 0 ̊C, 77%; ii. KOH, EtOH/H2O (2:1), rt, 97%; iii. CDI, DCM, rt; iv. CoA-SH-Li+3, 0.1 M 
NaHCO3 aq. / THF (1:1). 
 
Ethyl (E)-2-Methyldec-2-enoate (24)23 
 
 
 
Octanal (2.62 mL, 16.8 mmol) in anhydrous DCM (20 mL) was added dropwise to 23 (6.09 g, 16.8 
mmol) in anhydrous DCM (50 mL) at 0C and the reaction mixture was allowed to reach ambient 
temperature over 2 h. Evaporation and column chromatography (Pe /  EtOAc 50:1) gave 24 (2.74 g, 
77 %) as a colourless oil: 1H NMR (400.04 MHz, CDCl3) δ 6.75 (1H, tq, J = 7.5, 1.5 Hz), 4.17 (2H, 
q, J = 7.1 Hz), 2.19-2.11 (2H, m), 1.83-1.80 (3H, m), 1.49-1.37 (2H, m), 1.34-1.21 (11H, m), 0.90-
0.83 (3H, m). 
 
(E)-2-Methyldec-2-enoic acid (9)24 
 
 
 
Ethyl ester 24 (442 mg, 2.1 mmol) in EtOH (10 mL) was stirred with KOH (467 mg, 8.34 mmol) in 
H2O (5.0 mL) for 20 h. The reaction mixture was acidified to pH ~3 with aq. HCl (3 M) and the 
solvents were partly evaporated under reduced pressure. DCM was added to the residue and the 
organic layer was washed with water and brine. Drying (MgSO4), filtration, evaporation and 
column chromatography (DCM / MeOH 100:1) gave 9 (374 mg, 97%) as a colourless oil: 1H NMR 
(400.04 MHz, CDCl3) δ 11.70 (1H, br s), 6.91 (1H, tq, J = 7.5, 1.4 Hz), 2.23-2.15 (2H, m), 1.84-
1.81 (3H, m), 1.51-1.39 (2H, m), 1.36-1.20 (8H, m), 0.93-0.83 (3H, m). 
 
(E)-2-Methyldec-2-enoyl-CoA (4) 
 
Compound 4 was prepared from 9 (10 mg), following the same procedure as for compound 2R to 
give 3 mg of 4. 1H NMR (500.13 MHz, D2O): δ 8.62 (1H, s), 8.37 (1H, s), 6.75 (1H, dt, J = 7.8, 1.0 
Hz), 6.15 (1H, d, J = 6.0 Hz), 4.56 (1H, s), 4.18 (2H, s), 4.12-3.95 (2H, m), 3.84-3.75 (1H, m), 
3.57-3.48 (1H, m), 3.37 (2H, t, J = 6.4 Hz), 3.28 (2H, t, J = 6.4 Hz), 2.95 (2H, t, J = 6.5 Hz), 2.36 
(2H, t, J = 6.9 Hz), 2.18-2.11 (2H, m), 1.74 (3H, s), 1.40-1.05 (10H, m), 0.87 (3H, s), 0.76 (3H, t, J 
= 6.9 Hz), 0.70 (3H, s). 
 
AMACR assays1,2 
Human AMACR was expressed in E. coli Rosetta2 (DE3) at 22 °C overnight shaking at 220 r.p.m., 
inducting with 0.25 mM IPTG. Cells (~2 g) were lysed using the ‘one shot’ in ~30 mL 20 mM 
NaH2PO4-NaOH, 300 mM NaCl, 10 mM imidazole, pH 7.2 supplemented with 1 mM PMSF and 
250 u benzonase (Novagen) and stirred with N-lauroyl-sarcosine at 4 °C for 1 hour. Following 
centrifugation, enzyme was purified by metal-chelate chromatography, dialysed into 10 mM 
NaH2PO4-NaOH, pH 7.4 and stored at -80 °C. Protein purity of pooled fractions was ca. 95 – 98 % 
by SDS-PAGE analyses. Protein concentrations were quantified using UV-visible absorbance2 at 
280 nm (ε280 = 35785 M-1 cm-1) and assumed a molecular mass of 47146.8 Da. for the His-tag 
protein.1 
 
Assays were conducted in 50 mM NaH2PO4-NaOH, pH 7.4 containing ca. 85% 
2H2O and 100 µM 
acyl-CoA substrate as previously described, with negative controls contain heat-inactivated enzyme. 
±-Fenoprofenoyl-CoA or S-2-methyldecanoyl-CoA with wild-type enzyme were used as positive 
controls.1,2  Assays were quenched by heating to 50 °C for 10 minutes before 1H NMR analysis 
(500.13 MHz). Conversion of substrates was quantified by conversion of the 2-Me doublet at ca. 
1.0 p.p.m. into a singlet at ca. 1.75 p.p.m., and were corrected for non-enzymatic conversion in 
heat-inactivated negative controls.1,2 Kinetic assays contained 1.1 µg (0.023 nmol) protein per 
assay. Parameters were obtained using SigmaPlot 12. Data was analysed with the Direct Linear 
Plot25,26 and non-linear fitting of data to the Michaelis-Menten equation. Error bars are ± SE. 
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Time course of AMACR catalysed elimination reaction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S1: Time course of the AMACR catalysed elimination reaction. The reaction was carried 
out as described in the experimental using 100 µM substrate and 2.5 µM enzyme.  % conversion 
was calculated based on integration of the peaks at ca. 1.1 ppm (2R methyl group) and ca. 1.75 ppm 
(4 methyl group). A negative control containing heat-inactivated enzyme showed <5% conversion 
at all time points. 
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Kinetic analysis of anti-(3R,2R)-3-Fluoro-2-methyldecanoyl-CoA 2R 
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Enzyme Kinetics Nonlinear Fit Results 
 
 Notebook1 
 08/08/2013 12:04:26 
 Michaelis-Menten 
 Number of Replicates:   2 
 
 
 Parameters 
 Value ±Std. Error 95% Conf. Interval 
 Vmax 98.3751 14.1390 65.7699 to 130.9804 nmol.min.-1mg.-1 
 Km 25.5130 8.3049 6.3615 to 44.6645 μM 
 
 Goodness of Fit 
 Degrees of Freedom     8 
 AICc 45.403 
 R² 0.841 
 Sum of Squares 344.768 
 Sy.x   6.565 
 Runs Test p Value 0.500 
 
 Data 
 Number of x values     5 
 Number of replicates 2 
 Total number of values    10 
 Number of missing values     0 
 
  
Kinetic analysis of syn-(3R,2S)-3-Fluoro-2-methyldecanoyl-CoA 2S 
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 Notebook2 
 08/08/2013 13:55:15 
 Michaelis-Menten 
 Number of Replicates:   2 
 
 
 Parameters 
 Value ±Std. Error 95% Conf. Interval 
 Vmax 52.9457 9.8035 30.7681 to 75.1233 nmol.min.-1mg.-1 
 Km 30.4107 19.1990 -13.0214 to 73.8428 μM 
 
 Goodness of Fit 
 Degrees of Freedom     9 
 AICc 59.593 
 R² 0.605 
 Sum of Squares 1,051.835 
 Sy.x  10.811 
 Runs Test p Value 0.385 
 
 Data 
 Number of x values     6 
 Number of replicates 2 
 Total number of values    11 
 Number of missing values     1 
  
Unsaturated 2-methylacyl-CoA esters 3R and 3S as substrates for AMACR 
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Figure S1. 3R shows exchange of the α-proton in with live AMACR in 2H2O. This results in the 
doublet of the methyl group at 1.04 ppm becoming a singlet (outlined in green) and the concomitant 
conversion of the doublet of doublets for Ha at 5.29 ppm into a doublet (outlined in red). As 
exchange is an obligatory step in chiral inversion, it is highly likely that racemization also occurs. 
An identical reaction occurred upon incubation of 3S with AMACR under identical conditions (data 
not shown). 
 
 
 
 
 
